MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kwon, Duk Hwa ^a   Eom, Gwang Hyeon ^a   Ko, Jeong Hyeon ^a   Shin, Sera ^a   Joung, Hosouk ^a   Choe, Nakwon ^a   Nam, Yoon Seok ^a   Min, Hyun Ki ^a   Kook, Taewon ^a   Yoon, Somy ^a   Kang, Wanseok ^b   Kim, Yong Sook ^b   Kim, Hyung Seok ^a   Choi, Hyuck ^c   Koh, Jeong Tae ^c   Kim, Nacksung ^a   Ahn, Youngkeun ^b   Cho, Hyun Jai ^d   Lee, In Kyu ^e   Park, Dong Ho ^f   Suk, Kyoungho ^e   Seo, Sang Beom ^g   Wissing, Erin R ^h   Mendrysa, Susan M ^h   Nam, Kwang Il ^a   Kook, Hyun ^a   more..

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Chonnam National University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Kyungpook National University   (South Korea)

^f Kyungpook National University School of Medicine   (South Korea)

^g Chung Ang University   (South Korea)

^h PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; HISTONE DEACETYLASE 1; PROTEIN MDM2; UBIQUITIN PROTEIN LIGASE E3; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; CALCIUM; HDAC1 PROTEIN, HUMAN; HDAC1 PROTEIN, MOUSE; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE;

CALCIFICATION; CARDIOVASCULAR DISEASE; DEGRADATION; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITOR; METABOLISM; PEPTIDE; PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD VESSEL CALCIFICATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEGRADATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; UBIQUITINATION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALIA;

ANIMALS; CALCIUM; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE 1; HUMANS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; UBIQUITINATION; VASCULAR CALCIFICATION;

EID: 84956631216     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10492     Document Type: Article

References (62)

1. Frink, R. J., Achor, R. W., Brown, Jr A. L., Kincaid, O. W., Brandenburg, R. O. Significance of calcification of the coronary arteries. Am. J. Cardiol. 26, 241-247 (1970).
2. Fitzgerald, P. J., Ports, T. A., Yock, P. G. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation 86, 64-70 (1992).
3. Giachelli, C. M. Ectopic calcification: gathering hard facts about soft tissue mineralization. Am. J. Pathol. 154, 671-675 (1999).
4. Luo, G. et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78-81 (1997).
5. Kuro-o, M. et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45-51 (1997).
6. Lim, K. et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125, 2243-2255 (2012).
7. Spicer, S. S., Lewis, S. E., Tashian, R. E., Schulte, B. A. Mice carrying a CAR-2 null allele lack carbonic anhydrase II immunohistochemically and show vascular calcification. Am. J. Pathol. 134, 947-954 (1989).
8. Thornell, L., Carlsson, L., Li, Z., Mericskay, M., Paulin, D. Null mutation in the desmin gene gives rise to a cardiomyopathy. J. Mol. Cell. Cardiol. 29, 2107-2124 (1997).
9. Bucay, N. et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268 (1998).
10. Minucci, S., Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (2006).
11. Williams, S. M. et al. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J. Mol. Cell. Cardiol. 67, 112-125 (2014).
12. Guo, W., Shan, B., Klingsberg, R. C., Qin, X., Lasky, J. A. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am. J. Physiol. Lung. Cell. Mol. Physiol. 297, L864-L870 (2009).
13. Risebro, C. A. et al. Epistatic rescue of Nkx2.5 adult cardiac conduction disease phenotypes by prospero-related homeobox protein 1 and HDAC3. Circ. Res. 111, e19-e31 (2012).
14. Lee, T. M., Lin, M. S., Chang, N. C. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am. J. Physiol. Heart Circ. Physiol. 293, H968-H977 (2007).
15. Granger, A. et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22, 3549-3560 (2008).
16. Kee, H. J. et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113, 51-59 (2006).
17. Kong, Y. et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579-2588 (2006).
18. Gallo, P. et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res. 80, 416-424 (2008).
19. Azechi, T. et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J. Atheroscler. Thromb. 20, 538-547 (2013).
20. Sun, Y. et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ. Res. 111, 543-552 (2012).
21. Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672-2681 (2002).
22. Trion, A., Schutte-Bart, C., Bax, W. H., Jukema, J. W., van der Laarse, A. Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Mol. Cell. Biochem. 308, 25-33 (2008).
23. Giachelli, C. M. et al. Vascular calcification and inorganic phosphate. Am. J. Kidney Dis. 38, S34-S37 (2001).
24. Shao, J. S., Cai, J., Towler, D. A. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler. Thromb. Vasc. Biol. 26, 1423-1430 (2006).
25. Cho, H. J. et al. Vascular calcifying progenitor cells possess bidirectional differentiation potentials. PLoS Biol. 11, e1001534 (2013).
26. Abedin, M., Tintut, Y., Demer, L. L. Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. 24, 1161-1170 (2004).
27. Ivan, E. et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophagerich carotid artery lesions. Circulation 105, 2686-2691 (2002).
28. Hjerpe, R. et al. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 10, 1250-1258 (2009).
29. Hicke, L., Schubert, H. L., Hill, C. P. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol. 6, 610-621 (2005).
30. Cutrona, G. et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat. Biotechnol. 18, 300-303 (2000).
31. Oh, Y. M. et al. Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat. Cell Biol. 11, 295-302 (2009).
32. Gaughan, L., Logan, I. R., Neal, D. E., Robson, C. N. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res. 33, 13-26 (2005).
33. Logan, I. R. et al. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol. Cell. Biol. 26, 6502-6510 (2006).
34. Canettieri, G. et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat. Cell Biol. 12, 132-142 (2010).
35. Deshaies, R. J., Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434 (2009).
36. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000).
37. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
38. Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73, 2587-2597 (2013).
39. Lengner, C. J. et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol. 172, 909-921 (2006).
40. Walton, M. I., Wilson, S. C., Hardcastle, I. R., Mirza, A. R., Workman, P. An evaluation of the ability of pifithrin-alpha and-beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol. Cancer Ther. 4, 1369-1377 (2005).
41. Kim, B. G., Lee, J. H., Yasuda, J., Ryoo, H. M., Cho, J. Y. Phospho-Smad1 modulation by nedd4 E3 ligase in BMP/TGF-beta signaling. J. Bone. Miner. Res. 26, 1411-1424 (2011).
42. Kulikov, R. et al. Mdm2 facilitates the association of p53 with the proteasome. Proc. Natl Acad. Sci. USA 107, 10038-10043 (2010).
43. Carroll, P. E. et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18, 1935-1944 (1999).
44. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83 (1992).
45. Schroeder, T. M., Westendorf, J. J. Histone deacetylase inhibitors promote osteoblast maturation. J. Bone Miner. Res. 20, 2254-2263 (2005).
46. Lee, H. W. et al. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol. Endocrinol. 20, 2432-2443 (2006).
47. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., Karsenty, G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747-754 (1997).
48. Kook, H. et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 112, 863-871 (2003).
49. Jessberger, S. et al. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J. Neurosci. 27, 5967-5975 (2007).
50. Rao, R. S., Miano, J. M., Olson, E. N., Seidel, C. L. The A10 cell line: a model for neonatal, neointimal, or differentiated vascular smooth muscle cells? Cardiovasc. Res. 36, 118-126 (1997).
51. Kimes, B. W., Brandt, B. L. Characterization of two putative smooth muscle cell lines from rat thoracic aorta. Exp. Cell Res. 98, 349-366 (1976).
52. Phan, O. et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112, 2875-2882 (2005).
53. Lee, K. et al. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice. J. Immunol. 190, 1623-1630 (2013).
54. Price, P. A., Faus, S. A., Williamson, M. K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler. Thromb. Vasc. Biol. 20, 317-327 (2000).
55. Price, P. A., June, H. H., Buckley, J. R., Williamson, M. K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 21, 1610-1616 (2001).
56. Kang, W. S. et al. A macrophage-specific synthetic promoter for therapeutic application of adiponectin. Gene Ther. 21, 353-362 (2014).
57. Nam, D. et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 297, H1535-H1543 (2009).
58. Potthoff, M. J. et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J. Clin. Invest. 117, 2459-2467 (2007).
59. Ye, F., Lattif, A. A., Xie, J., Weinberg, A., Gao, S. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells. Cell Cycle 11, 1393-1399 (2012).
60. Montgomery, R. L. et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21, 1790-1802 (2007).
61. Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., Olson, E. N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl Acad. Sci. USA 106, 7751-7755 (2009).
62. Eom, G. H. et al. Regulation of acetylation of histone deacetylase 2 by p300/CBP-Associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ. Res. 114, 1133-1143 (2014).